




Amendments to the Claims

The following listing of claims will replace all prior versions and listings of claims in the application.


Listing of Claims

Claims 1-70 (canceled).

71. (currently amended) A compound of the Formula I:



or a pharmaceutically acceptable salt thereof, wherein:




is a thiazole or isoxazole, wherein:

the thiazole or isoxazole is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, nitro, alkoxy, hydroxyalkyl, thioalkyl, amino, alkylamino, arylamino, alkylsulfonamide, acyl, acylamino, alkylsulfone, sulfonamide, allyl, alkenyl, methylenedioxy, ethylenedioxy, alkynyl, carboxamide, cyano, and $-(CH_2)_mCOR$;


each m is independently zero, 1, or 2;

each R is independently selected from the group consisting of hydroxy, alkoxy, alkyl, amino, and sulfone;


A¹ is selected from the group consisting of:



,



, and



;

wherein any such substituent is optionally substituted by one or more substituents independently selected from the group consisting of hydroxy, alkyl, alkoxy, alkoxyalkyl, thioalkyl, haloalkyl, cyano, amino, alkylamino, halogen, acylamino, sulfonamide, and $-\text{COR}^4$;

X^{10} is CH_2 , O, S, SO_2 , CO, CF_2 , or $\text{C}(\text{CH}_3)_2$;

X^{11} is CH_2 , O, S, SO_2 , CO, CF_2 , or $\text{C}(\text{CH}_3)_2$;

X^{12} is CH_2 , O, S, SO_2 , CO, or $\text{C}(\text{CH}_3)_2$;

R^{10} is H, CH_3 , OCH_3 , OH, or NR_2 ;

R^{11} is H, CH_3 , OCH_3 , OH, or NR_2 ;

R^{12} is H, CH_3 , OCH_3 , or OH;

each R^4 is independently hydroxy, alkoxy, alkyl, or amino;

as to Z_1 and Z_2 :

Z_1 is selected from the group consisting of CH_2 , O, CH_2O , NH, CO, S, SO, $\text{CH}(\text{OH})$, and SO_2 ; and Z_2 is a 1-5 carbon linker optionally containing one or more heteroatoms independently selected from the group consisting of O, S, and N; or

$\text{Z}_1 - \text{Z}_2$ contains a moiety selected from the group consisting of carboxamide, sulfone, sulfonamide, alkenyl, alkynyl, and acyl; or

$\text{Z}_1 - \text{Z}_2$ contains a 5- or 6-membered aryl or heteroaryl ring, wherein:

the heteroaryl ring optionally is substituted with R^c , and

the heteroaryl ring contains 1-3 heteroatoms independently selected from the group consisting of O, N, and S;

each R^c is independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, alkoxy, carboxamide, and cyano;

the carbon and nitrogen atoms of Z₁ - Z₂ are optionally substituted by a moiety selected from the group consisting of alkyl, alkoxy, thioalkyl, alkylsulfone, aryl, alkoxyalkyl, hydroxy, alkylamino, heteroaryl, alkenyl, alkynyl, carboxyalkyl, halogen, haloalkyl, and acylamino;

as to X and Y:

X-Y contains a moiety selected from the group consisting of acyl, alkyl, sulfonyl, amino, ether, thioether, carboxamido, sulfonamido, aminosulfonyl and olefins; or

X is selected from the group consisting of -CHR^e-, -NR^f-, -O-, -S-, -SO₂-, and -CO-; and Y is selected from the group consisting of (CH₂)_p, -CHR^g-, -NR^g-, CO, and SO₂;

R^e is selected from the group consisting of H, lower alkyl, alkoxy, cycloalkyl, alkoxyalkyl, hydroxy, alkynyl, alkenyl, haloalkyl, thioalkyl, and aryl, wherein:

when R^e is hydroxy, the hydroxy group can optionally form a lactone with the carboxylic acid function of the chain;

R^f is selected from the group consisting of H, alkyl, aryl, benzyl, and haloalkyl;

each R^g is independently selected from the group consisting of H, alkyl, haloalkyl, alkoxyalkyl, alkynyl, aryl, heteroaryl, aralkyl, hydroxy, alkoxy, and carboxyalkyl;

p is zero or 1;


as to Y³ and Y⁴:

Y³ and Y⁴ are independently selected from the group consisting of H, alkyl, haloalkyl, halogen, aryl, aralkyl, heteroaralkyl, heteroaryl, alkenes, hydroxyalkyl, and alkyne, wherein:

the alkyl chain is straight or branched and optionally contains one or more moieties independently selected from the group consisting of N, O, S, sulfone, [[sulfonamide]] sulfonamide, nitrile, carboxamide, carboalkoxy, or carboxyl, and the aryl and heteroaryl rings:

are monocyclic or bicyclic optionally containing 1-5 heteroatoms,

may be saturated or unsaturated, and
may optionally be substituted by one or more R^c substituents; or
 Y^3 and Y^4 together form a 3-8 membered monocyclic or a 7-11 membered
bicyclic ring B such that the compound of Formula I corresponds in structure to formula
IA:



wherein ring B:

optionally contains one or more double bonds,
optionally contains one or more moieties independently selected from the
group consisting of O, NR^g , S, CO, and SO_2 , and
optionally is substituted with one or more substituents selected from the
group consisting of alkyl, haloalkyl, halogen, haloalkyl, alkoxy, alkyne, cyano,
alkylsulfone, sulfonamide, carboalkoxy, and carboxyalkyl;

Y^5 is C or N when Y^3 or Y^4 is H;

Y^5 is C when Y^3 and Y^4 are both other than H;

R^b is $X_2 - R^h$;

X_2 is selected from the group consisting of O, S, and NR^j ; and

R^h and R^j are independently selected from the group consisting of H, alkyl, aryl, aralkyl,
acyl, and alkoxyalkyl.

72. (previously presented) A compound according to claim 71, wherein:

X is $-CHR^e-$;

R^e is H;


Y is $-(CH_2)_p$;

p is zero;


Y^5 is a carbon; and

R^b is OH.

73. (currently amended) A compound of the following formula:



or a pharmaceutically acceptable salt thereof, wherein:





is a thiazole or isoxazole, wherein:

the thiazole or isoxazole is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, nitro, alkoxy, hydroxyalkyl, thioalkyl, amino, alkylamino, arylamino, alkylsulfonamide, acyl, acylamino, alkylsulfone, sulfonamide, allyl, alkenyl, methylenedioxy, ethylenedioxy, alkynyl, carboxamide, cyano, and $-(CH_2)_mCOR$;


each m is independently zero, 1, or 2;

each R is independently selected from the group consisting of hydroxy, alkoxy, alkyl, amino, and sulfone;

A¹ is selected from the group consisting of:



, and



wherein any such substituent is optionally substituted by one or more substituents independently selected from the group consisting of hydroxy, alkyl, alkoxy, alkoxyalkyl, thioalkyl, haloalkyl, cyano, amino, alkylamino, halogen, acylamino, sulfonamide, and -COR⁴;

X¹⁰ is CH₂, O, S, SO₂, CO, CF₂, or C(CH₃)₂;

X¹¹ is CH₂, O, S, SO₂, CO, CF₂, or C(CH₃)₂;

X¹² is CH₂, O, S, SO₂, CO, or C(CH₃)₂;

R¹⁰ is H, CH₃, OCH₃, OH, or NR₂;

R¹¹ is H, CH₃, OCH₃, OH, or NR₂;

R¹² is H, CH₃, OCH₃, or OH;

each R⁴ is independently hydroxy, alkoxy, alkyl, or amino;

as to Z₁ and Z₂:

Z₁ is selected from the group consisting of CH₂, O, CH₂O, NH, CO, S, SO, CH(OH), and SO₂; and Z₂ is a 1-5 carbon linker optionally containing one or more heteroatoms independently selected from the group consisting of O, S, and N; or

Z₁ - Z₂ contains a moiety selected from the group consisting of carboxamide, sulfone, sulfonamide, alkenyl, alkynyl, and acyl; or

Z₁ - Z₂ contains a 5- or 6-membered aryl or heteroaryl ring, wherein:








the heteroaryl ring optionally is substituted with R^c, and

the heteroaryl ring contains 1-3 heteroatoms independently selected from the group consisting of O, N, and S;

each R^c is independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, alkoxy, carboxamide, and cyano;

the carbon and nitrogen atoms of Z₁ - Z₂ are optionally substituted by a moiety selected from the group consisting of alkyl, alkoxy, thioalkyl, alkylsulfone, aryl, alkoxyalkyl, hydroxy, alkylamino, heteroaryl, alkenyl, alkynyl, carboxyalkyl, halogen, haloalkyl, and acylamino;

Y^3 is selected from the group consisting of H, alkyl, $CH_2B_1R^{20}$, CH_2OH , $C\equiv C-R^{21}$,



B_1 is O, SO_2 , S, or CO;

R^{20} is alkyl or aryl;

R^{21} is alkyl, aryl, or alkoxyalkyl;

R^{22} is H, alkyl, OCH_3 , OH, halogen, amino, or CN;

R^{23} is H, alkyl, OCH_3 , OH, halogen, amino, or CN;

R^{24} is H, alkyl, OCH_3 , OH, or halogen;

X^{20} is CH_2 or O;

X^{21} is NH, NCH_3 , O, or S; and


Y^4 is selected from the group consisting of H, alkyl, haloalkyl, halogen, aryl, arakyl, heteroaralkyl, heteroaryl, alkenes, hydroxyalkyl, and alkyne, wherein:

the alkyl chain is straight or branched and optionally contains one or more moieties independently selected from the group consisting of N, O, S, sulfone, [[sulfonamide]] sulfonamide, nitrile, carboxamide, carboalkoxy, or carboxyl, and the aryl and heteroaryl rings:


are monocyclic or bicyclic optionally containing 1-5 heteroatoms, may be saturated or unsaturated, and

may optionally be substituted by one or more R^c substituents.

74. (currently amended) A compound of the following formula:



or a pharmaceutically acceptable salt thereof, wherein:





is a thiazole or isoxazole, wherein:


the thiazole or isoxazole is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, nitro, alkoxy, hydroxyalkyl, thioalkyl, amino, alkylamino, arylamino, alkylsulfonamide, acyl, acylamino, alkylsulfone, sulfonamide, allyl, alkenyl, methylenedioxy, ethylenedioxy, alkynyl, carboxamide, cyano, and $-(CH_2)_mCOR$;

each m is independently zero, 1, or 2;

each R is independently selected from the group consisting of hydroxy, alkoxy, alkyl, amino, and sulfone;

A^1 is selected from the group consisting of:





wherein any such substituent is optionally substituted by one or more substituents independently selected from the group consisting of hydroxy, alkyl, alkoxy, alkoxyalkyl, thioalkyl, haloalkyl, cyano, amino, alkylamino, halogen, acylamino, sulfonamide, and -COR⁴;

X¹⁰ is CH₂, O, S, SO₂, CO, CF₂, or C(CH₃)₂;

X¹¹ is CH₂, O, S, SO₂, CO, CF₂, or C(CH₃)₂;

X¹² is CH₂, O, S, SO₂, CO, or C(CH₃)₂;

R¹⁰ is H, CH₃, OCH₃, OH, or NR₂;

R¹¹ is H, CH₃, OCH₃, OH, or NR₂;

R¹² is H, CH₃, OCH₃, or OH;

each R⁴ is independently hydroxy, alkoxy, alkyl, or amino;

as to Z₁ and Z₂:

Z₁ is selected from the group consisting of CH₂, O, CH₂O, NH, CO, S, SO, CH(OH), and SO₂; and Z₂ is a 1-5 carbon linker optionally containing one or more heteroatoms independently selected from the group consisting of O, S, and N; or

Z₁ - Z₂ contains a moiety selected from the group consisting of carboxamide, sulfone, sulfonamide, alkenyl, alkynyl, and acyl; or

Z₁ - Z₂ contains a 5- or 6-membered aryl or heteroaryl ring, wherein:


the heteroaryl ring optionally is substituted with R^c, and

the heteroaryl ring contains 1-3 heteroatoms independently selected from the group consisting of O, N, and S;

each R^c is independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, alkoxy, carboxamide, and cyano;

the carbon and nitrogen atoms of Z₁ - Z₂ are optionally substituted by a moiety selected from the group consisting of alkyl, alkoxy, thioalkyl, alkylsulfone, aryl, alkoxyalkyl, hydroxy, alkylamino, heteroaryl, alkenyl, alkynyl, carboxyalkyl, halogen, haloalkyl, and acylamino;

Y³ is selected from the group consisting of H, methyl, phenyl, ethyl, propyl, isopropyl, phenylmethoxymethyl,




Y⁴ is selected from the group consisting of H, alkyl, haloalkyl, halogen, aryl, aralkyl, heteroaralkyl, heteroaryl, alkenes, hydroxyalkyl, and alkyne, wherein:

the alkyl chain is straight or branched and optionally contains one or more moieties independently selected from the group consisting of N, O, S, sulfone, [[sulfonamide]] sulfonamide, nitrile, carboxamide, carboalkoxy, or carboxyl, and

the aryl and heteroaryl rings:

are monocyclic or bicyclic optionally containing 1-5 heteroatoms,
may be saturated or unsaturated, and
may optionally be substituted by one or more R^c substituents.

75. (previously presented) A compound according to claim 74, wherein A¹ is



76. (previously presented) A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

(2-{5-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-cyclopropyl)-acetic acid;

3-Phenyl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-Pyridin-3-yl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-Benzo[1,3]dioxol-5-yl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

3-Pyridin-3-yl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

3-Benzo[1,3]dioxol-5-yl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

(2-{3-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-cyclopropyl)-acetic acid;

(2-{4-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-cyclopropyl)-acetic acid;

3-Phenyl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-Pyridin-3-yl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-Benzo[1,3]dioxol-5-yl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-Phenyl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid;

3-Pyridin-3-yl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid;

3-Benzo[1,3]dioxol-5-yl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid

(2-{5-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-cyclopropyl)-acetic acid;

3-Phenyl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-Pyridin-3-yl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-Benzo[1,3]dioxol-5-yl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

3-Pyridin-3-yl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

3-Benzo[1,3]dioxol-5-yl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

(2-{3-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-cyclopropyl)-acetic acid;

(2-{4-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-cyclopropyl)-acetic acid;

3-Phenyl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-Pyridin-3-yl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-Benzo[1,3]dioxol-5-yl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

Phenyl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid;

3-Pyridin-3-yl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid; and

3-Benzo[1,3]dioxol-5-yl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid.

77. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 71 and a pharmaceutically acceptable carrier.

78. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of Claim 76 and a pharmaceutically acceptable carrier.

79. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of at least one compound or salt of Claim 71 and a pharmaceutically acceptable carrier/or additive and optionally a cytotoxic agent.

80. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of at least one compound or salt of Claim 76 and a pharmaceutically acceptable carrier/or additive and optionally a cytotoxic agent.

81. (currently amended) A method for treating a condition ~~mediated by $\alpha_v\beta_3$ -integrin~~ selected from the group consisting of tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atherosclerosis, macular degeneration, retinopathy and arthritis in a mammal in need of such treatment comprising administering an effective $\alpha_v\beta_3$ inhibiting amount of a compound or salt of Claim 71.

82. (currently amended) A method for treating a condition ~~mediated by $\alpha_v\beta_3$ integrin~~ selected from the group consisting of tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atherosclerosis, macular degeneration, retinopathy and arthritis in a mammal in need of such treatment comprising administering an effective $\alpha_v\beta_3$ inhibiting amount of a compound or salt of claim 76.

Claims 83-84 (canceled).

85. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 73 and a pharmaceutically acceptable carrier.

86. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of at least one compound or salt of claim 73 and a pharmaceutically acceptable carrier/or additive and optionally a cytotoxic agent.

87. (currently amended) A method for treating a condition ~~mediated by $\alpha_v\beta_3$ integrin~~ selected from the group consisting of tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atherosclerosis, macular degeneration, retinopathy and arthritis in a mammal in need of such treatment comprising administering an effective $\alpha_v\beta_3$ inhibiting amount of a compound or salt of claim 73.

Claim 88 (canceled).


89. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 74 and a pharmaceutically acceptable carrier.

90. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of at least one compound or salt of claim 74 and a pharmaceutically acceptable carrier/or additive and optionally a cytotoxic agent.


91. (currently amended) A method for treating a condition ~~mediated by $\alpha_v\beta_3$ integrin~~ selected from the group consisting of tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atherosclerosis, macular degeneration, retinopathy and arthritis in a mammal in need of such treatment comprising administering an effective $\alpha_v\beta_3$ inhibiting amount of a compound or salt of claim 74.

Claim 92 (canceled).

93. (currently amended) A compound of the Formula I:



or a pharmaceutically acceptable salt thereof, wherein:






is a thiazole or isoxazole, wherein:

the thiazole or isoxazole is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, nitro, alkoxy, hydroxyalkyl, thioalkyl, amino, alkylamino, arylamino, alkylsulfonamide, acyl, acylamino, alkylsulfone, sulfonamide, allyl, alkenyl, methylenedioxy, ethylenedioxy, alkynyl, carboxamide, cyano, and $-(CH_2)_mCOR$;

each m is independently zero, 1, or 2;

each R is independently selected from the group consisting of hydroxy, alkoxy, alkyl, amino, and sulfone;

A¹ is selected from the group consisting of:



wherein any such substituent is optionally substituted by one or more substituents independently selected from the group consisting of hydroxy, alkyl, alkoxy, alkoxyalkyl, thioalkyl, haloalkyl, cyano, amino, alkylamino, halogen, acylamino, sulfonamide, and -COR⁴;

X¹⁰ is CH₂, O, S, SO₂, CO, CF₂, or C(CH₃)₂;

X¹¹ is CH₂, O, S, SO₂, CO, CF₂, or C(CH₃)₂;

X¹² is CH₂, O, S, SO₂, CO, or C(CH₃)₂;

R¹⁰ is H, CH₃, OCH₃, OH, or NR₂;

R¹¹ is H, CH₃, OCH₃, OH, or NR₂;

R¹² is H, CH₃, OCH₃, or OH;

each R⁴ is independently hydroxy, alkoxy, alkyl, or amino;

as to Z₁ and Z₂:

Z₁ is selected from the group consisting of CH₂, O, CH₂O, NH, CO, S, SO, CH(OH), and SO₂; and Z₂ is a 1-5 carbon linker optionally containing one or more heteroatoms independently selected from the group consisting of O, S, and N; or

Z₁ - Z₂ contains a moiety selected from the group consisting of carboxamide, sulfone, sulfonamide, alkenyl, alkynyl, and acyl; or

Z₁ - Z₂ contains a 5- or 6-membered aryl or heteroaryl ring, wherein:

the heteroaryl ring optionally is substituted with R^c, and

the heteroaryl ring contains 1-3 heteroatoms independently selected from the group consisting of O, N, and S;

each R^c is independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, alkoxy, carboxamide, and cyano;


the carbon and nitrogen atoms of Z₁ - Z₂ are optionally substituted by a moiety selected from the group consisting of alkyl, alkoxy, thioalkyl, alkylsulfone, aryl, alkoxyalkyl, hydroxy, alkylamino, heteroaryl, alkenyl, alkynyl, carboxyalkyl, halogen, haloalkyl, and acylamino;

Y is selected from the group consisting of (CH₂)_p, -CHR^g-, -NR^g-, CO, and SO₂;

each R^g is independently selected from the group consisting of H, alkyl, haloalkyl, alkoxyalkyl, alkynyl, aryl, heteroaryl, aralkyl, hydroxy, alkoxy, and carboxyalkyl;

p is zero or 1;

X and Y³ together form a 3-7 membered monocyclic ring C such that the compound of Formula I corresponds in structure to formula IB:



wherein ring C:

optionally contains one or more double bonds,

optionally contains one or more moieties independently selected from the group consisting of O, NR^g, S, CO, and SO₂, and

optionally is substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, alkoxy, haloalkyl, hydroxyalkyl, and alkoxyalkyl;

Y⁴ is selected from the group consisting of H, alkyl, haloalkyl, halogen, aryl, aralkyl, heteroaralkyl, heteroaryl, alkenes, hydroxyalkyl, and alkyne, wherein:

the alkyl chain is straight or branched and optionally contains one or more moieties independently selected from the group consisting of N, O, S, sulfone, [[sulfonamide]] sulfonamide, nitrile, carboxamide, carboalkoxy, or carboxyl, and

the aryl and heteroaryl rings:

are monocyclic or bicyclic optionally containing 1-5 heteroatoms,

may be saturated or unsaturated, and

may optionally be substituted by one or more R^c substituents; or

R^b is X₂ - R^h;

X₂ is selected from the group consisting of O, S, and NR^j; and

R^h and R^j are independently selected from the group consisting of H, alkyl, aryl, aralkyl, acyl, and alkoxyalkyl.

94. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 93 and a pharmaceutically acceptable carrier.

95. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of at least one compound or salt of claim 93 and a pharmaceutically acceptable carrier/or additive and optionally a cytotoxic agent.

96. (currently amended) A method for treating a condition ~~mediated by $\alpha_v\beta_3$ integrin~~ selected from the group consisting of tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atherosclerosis, macular degeneration, retinopathy and arthritis in a mammal in need of such treatment comprising administering an effective $\alpha_v\beta_3$ inhibiting amount of a compound or salt of claim 93.

Claim 97 (canceled).